HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desaphy, J.-F. Articles by Conte Camerino, D. Search for Related Content PubMed PubMed Citation Articles by Desaphy, J.-F. Articles by Conte Camerino, D. Related Collections Muscle disease Ion channel gene defects

Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative

From the Unit of Pharmacology (Drs. Desaphy, De Luca, Tortorella, and Conte Camerino), Department of Pharmaco-Biology (Dr. De Vito), Faculty of Pharmacy, University of Bari, Italy; and Division of Genetic Medicine (Dr. George), Vanderbilt University, Nashville, TN.

Address correspondence and reprint requests to Dr. Diana Conte Camerino, Unità di Farmacologia, Dipartimento Farmaco-Biologico, Facoltà di Farmacia, Università di Bari, via Orabona 4–Campus, 70125 Bari, Italy; e-mail: conte{at}farmbiol.uniba.it

Background:— Myotonia and periodic paralysis caused by sodium channel mutations show variable responses to the anti-myotonic drug mexiletine.

Objective:— To investigate whether variability among sodium channel mutants results from differences in drug binding affinity or in channel gating.

Methods:— Whole-cell sodium currents (I_Na) were recorded in tsA201 cells expressing human wild-type (WT) and mutant skeletal muscle sodium channels (A1156T, hyperkalemic periodic paralysis; R1448C, paramyotonia congenita; G1306E, potassium-aggravated myotonia).

Results:— At a holding potential (hp) of -120 mV, mexiletine produced a tonic (TB, 0.33 Hz) and a use-dependent (UDB, 10 Hz) block of peak I_Na with a potency following the order rank R1448C > WT A1156T > G1306E. Yet, when assayed from an hp of -180 mV, TB and UDB by mexiletine were similar for the four channels. The different midpoints of channel availability curves found for the four channels track the half-maximum inhibitory value (IC₅₀) measured at -120 mV. Thus differences in the partitioning of channels between the closed and fast-inactivated states underlie the different IC₅₀ measured at a given potential. The mexiletine-derivative, Me7 (-[(2-methylphenoxy)methyl]-benzenemethanamine), behaved similarly but was 5 times more potent than mexiletine. Interestingly, the higher drug concentrations ameliorated the abnormally slower decay rate of myotonic I_Na.

Conclusions:— These results explain the basis of the apparent difference in block of mutant sodium channels by mexiletine and Me7, opening the way to a more rationale drug use and to design more potent drugs able to correct specifically the biophysical defect of the mutation in individual myotonic patients.

This article has been cited by other articles:

				Y. Ruan, N. Liu, R. Bloise, C. Napolitano, and S. G. Priori Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients Circulation, September 4, 2007; 116(10): 1137 - 1144. [Abstract] [Full Text] [PDF]

				J.-F. Desaphy, A. D. E. Luca, M. P. Didonna, A. L. George Jr, and D. C. Camerino Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block J. Physiol., January 15, 2004; 554(2): 321 - 334. [Abstract] [Full Text] [PDF]

				A. De Luca, S. Talon, M. De Bellis, J.-F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. Franchini, V. Tortorella, and D. C. Camerino Optimal Requirements for High Affinity and Use-Dependent Block of Skeletal Muscle Sodium Channel by N-Benzyl Analogs of Tocainide-Like Compounds Mol. Pharmacol., October 1, 2003; 64(4): 932 - 945. [Abstract] [Full Text] [PDF]

				C. E. Clancy, M. Tateyama, H. Liu, X. H.T. Wehrens, and R. S. Kass Non-Equilibrium Gating in Cardiac Na+ Channels: An Original Mechanism of Arrhythmia Circulation, May 6, 2003; 107(17): 2233 - 2237. [Abstract] [Full Text] [PDF]

				J.-F. Desaphy, S. Pierno, A. De Luca, P. Didonna, and D. C. Camerino Different Ability of Clenbuterol and Salbutamol to Block Sodium Channels Predicts Their Therapeutic Use in Muscle Excitability Disorders Mol. Pharmacol., March 1, 2003; 63(3): 659 - 670. [Abstract] [Full Text] [PDF]

				H. Liu, M. Tateyama, C. E. Clancy, H. Abriel, and R. S. Kass Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na+ Channels by Flecainide: Evidence from the Analysis of Disease-linked Mutations J. Gen. Physiol., June 24, 2002; 120(1): 39 - 51. [Abstract] [Full Text] [PDF]